Optimization of diarylazines as anti-HIV agents with dramatically by Bollini, Mariela et al.
Optimization of diarylazines as anti-HIV agents with dramatically
enhanced solubility
Mariela Bollinia, José A. Cisnerosa, Krasimir A. Spasovb, Karen S. Andersonb, and William
L. Jorgensena
aDepartment of Chemistry, Yale University, New Haven, CT 06520-8107, USA
bDepartment of Pharmacology, Yale University School of Medicine, New Haven, CT 06520-8066,
USA
Abstract
Non-nucleoside inhibitors of HIV-1 reverse transcriptase are reported that have ca. 100-fold
greater solubility than the structurally related drugs etravirine and rilpivirine, while retaining high
anti-viral activity. The solubility enhancements come from strategic placement of a
morpholinylalkoxy substituent in the entrance channel of the NNRTI binding site. Compound 4d
shows lownanomolar activity similar to etravirine towards wild-type HIV-1 and key viral variants.
The use of non-nucleoside inhibitors of HIV-1 reverse transcriptase (C) is commonplace for
treatment of HIV infection.1,2 Among the five FDA-approved drugs in the class, the most
recent introductions have been etravirine and rilpivirine. These diarylpyrimidines provide
much improved performance in cell assays against variant forms of HIV-1 that incorporate
mutations in the vicinity of the NNRTI binding site.3,4 The earliest approved NNRTIs,
nevirapine and delavirdine, are debilitated by most common mutations. Though the second-
generation compound, efavirenz, performs well against variants bearing the clinically
prevalent Tyr181Cys mutation, resistance arises from other common variants such as those
including Lys103Asn.2-4 The clinical significance of efavirenz and rilpivirine is particularly
great since they are incorporated into the once-a-day combination therapies Atripla and
Complera, respectively.5 The other two active components of the pills are the same, the
nucleosides emtricitabine and tenofovir. Though the performance in cell-based assays is far
better for rilpivirine than for efavirenz, surprisingly more virologic failure is observed for
patients under treatment with Complera than Atripla.5-7 Thus, from this observation and the
desire to further diminish dosages and side effects, improvements are still possible for the
NNRTI class.
© 2013 Elsevier Ltd. All rights reserved.
Correspondence to: Karen S. Anderson; William L. Jorgensen.
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
NIH Public Access
Author Manuscript
Bioorg Med Chem Lett. Author manuscript; available in PMC 2014 September 15.
Published in final edited form as:
Bioorg Med Chem Lett. 2013 September 15; 23(18): 5213–5216. doi:10.1016/j.bmcl.2013.06.091.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
A particular issue with aminoazine NNRTIs has been poor solubility, which often has
undesirable ramifications including low bioavailability, difficulties in formulation, and
accumulation in fatty tissues.8,9 Most oral drugs have an aqueous solubility (S) in the range
10-5 to 10-2 M, which for a drug with a molecular weight of 400, corresponds to 4 to 4,000
μg/mL. It is very rare for an FDA-approved oral drug to have a solubility near neutral pH
below 10-6 M.9 However, rilpivirine “is practically insoluble in water (20 ng/mL at pH
7.0) ”,4 which translates to an S of 5 × 10-8 M. It appears to have an unusual absorption
mechanism involving aggregates.10 For etravirine, the solubility is also “≪1 μg/mL”, and
extensive formulation work was needed to bring the daily dosage to 0.4 g per day.11
Furthermore, in view of its low solubility, dapivirine is being evaluated as a vaginal
microbicide.12 This was also the fate of UC-781, an earlier, NNRTI with poor solubility
(<30 ng/mL).13 Interestingly, the daily dosage for nevirapine, like etravirine, is 0.4 g despite
the fact that its potency towards WT HIV-1 is ca. 100-fold less than for etravirine. An
important factor is undoubtedly that the observed aqueous solubility of nevirapine is 167 μg/
mL (10-3.2 M).14 Nevirapine demonstrates that it is possible to have a viable NNRTI that has
an EC50 of ca. 100 nM in cell assays, if the compound has good solubility and
bioavailability.
Poor solubility has also been an issue with aminoazine-containing NNRTIs (1) from our
laboratory. In view of the structural overlap of 1, the TMC compounds, and UC-781, it is
not surprising that the measured solubility of 1 (R = H, R′ = Me) is 0.1 μg/mL.15 In order to
improve the solubility of such aminoazines, extensive modeling, synthesis, assaying and
crystallography were undertaken that demonstrated that it was possible to attach a
solubilizing substituent as OR′ that would extend into the entrance channel of the NNRTI
binding site.15,16 Specifically, 2 has S = 42 μg/mL, while retaining an EC50 of 92 nM in a
standard assay using MT-2 cells infected with WT HIV-1.15
In the present communication, results are presented for applying this strategy to improve the
solubility of diarylpyrimidines and triazines by investigating 3 and 4 (Scheme 1). Synthesis
of the compounds proceeded as indicated via three SNAr reactions.17 The final intermediate
7 was also reduced to obtain the corresponding analogs 8 and 9 lacking the
morpholinoalkoxy group. The identities of all assayed compounds were confirmed by 1H
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and 13C NMR and high-resolution mass spectrometry; purity was >95% as judged by high-
performance liquid chromatography.
Activities against the IIIB and variant strains of HIV-1 were measured using MT-2 human
T-cells, as previously described.16,18 EC50 values are obtained as the dose required to
achieve 50% protection of the infected cells by the MTT colorimetric method. CC50 values
for inhibition of MT-2 cell growth by 50% are obtained simultaneously. Solubility
measurements used a shake-flask protocol with triplicate samples.19 The compounds were
dissolved in Britton-Robinson buffer and stirred in vials for 48 hours at 25 °C. The pH of the
buffer solutions was measured by a Corning General Purpose pH Combination probe
(4136L21). The solution containing excess solid was filtered using a Whatman Mini-
UniPrep syringeless filter device with a 0.45 μm pore size, and the supernatant was analyzed
by UV-vis spectrophotometry (Agilent 8453). Piroxicam was used as a reference compound;
our solubility result of 7.2 μg/mL compares well with the prior report of 6.4 μg/mL.19
The results of the anti-viral assays are presented in Table 1. Our synthesized TMC120 (8a)
yielded 0.7 nM potency in the WT assay and 39 nM results for both the Y181C and K103N/
Y181C variants. This can be compared with previous results of 1.2, 7, and 54 nM using
MT-4 cells.4 The other compound that was previously reported, the triazine 9a, was found
here to have 2.3, 47, and 90 nM EC50 values, while the MT-4 assays yielded 0.3, 8, and 50
nM.20 Thus, the accord is reasonable except that it appears that the Y181C containing strain
used here is more challenging.
Appendage of the morpholinoethoxy substituent to 1 (R = H, R′ = Me) to yield 2 causes a 9-
fold reduction in WT potency,15 while the modification of pyrimidine 8a to yield 3a and 3b
results in 10- to 20-fold declines. Though the compounds are still potent NNRTIs towards
WT virus, the EC50 results of 700 and 480 nM for the Y181C-bearing variant are more
problematic. However, the impressive performance of 3b towards the challenging double
mutant is notable. The corresponding triazine 4b fares even better with 8, 310, and 31 nM
EC50 values. Thus, these results encouraged further study of triazine analogs. Replacement
of the 4-Me substituent of the mesityl group by cyano and cyanovinyl was explored and
provided the remarkably potent 4d with EC50 results of 1, 12, and 1 nM for the WT and
mutant HIV-1 strains. 4d may be viewed as a triazine relative of rilpivirine with a
strategically added morpholinopropoxy group. Its activity results are very similar to those
obtained here for etravirine. 2,6-difluorophenyl alternatives 4e - 4i with various 4-R groups
were also considered, but did not surpass the overall performance of 4d. However, the 4-
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methyl analog 4e was strikingly potent, 190 pM, in the WT assay. Only one NNRTI with
greater anti-HIV activity has been previously reported.18
The solubility results are summarized in Table 2. Consistent with the results for 1 and 2,15
the addition of the morpholinoalkoxy groups has profound effects with 83- and 182-fold
increases in S in going from TMC120 (8a) to 3a and 3b. The aqueous solubilty of the
corresponding triazine 9a is also very low (0.2 μg/mL); large enhancements are again
delivered by the morpholinoalkoxy analogs. Notably, 4d has a solubility of 14.2 μg/mL,
which is 100-fold greater than for dapivirine (TMC120, 8a) and 59- and 710-fold greater
than the prior reports for rilpivirine.
As demonstrated crystallographically for 2, it is expected that the morpholinoalkoxy side
chains for the present compounds in complex with HIV-1 reverse transcriptase extend past
Glu138 into the entrance channel of the NNRTI binding site.15,16 An illustration for 4b is
provided in Figure 1, as created by modeling with the BOMB and MCPRO programs22,23
using the OPLS/CM1A force field24 starting with the 1S9E crystal structure, which has an
anilinyltriazine as the ligand.25 Consistent with the modeling and crystallography for 2,15
the contacts in the NNRTI binding site are normal and the morpholinopropoxy side chain
extends past Glu138 towards Glu28. A salt bridge, which is sometimes observed between
Glu138 and Lys101, cannot be present to allow the passage. With the (CH2)3 spacer a salt-
bridge between Gu138 and the protonated morpholine is unlikely. However, if Glu28
reoriented, it could be in close contact with the morpholine terminus. This suggested
possible benefit of replacing the ether oxygen with a positively charged group. Thus, the
piperidine analogs 10a and 10b were synthesized (Scheme 2), but they turned out to be 2-3-
fold less potent than the corresponding morpholine analogs 4a and 4b (Table 1). The
intended salt-bridge is largely solvent-exposed and in competition with the Glu28-Lys32
interaction.
In summary, structural analyses suggested the possibility of appending solubilizing groups
to the diarylazine class of NNRTIs at the 6-position in the azine ring. The strategy was
successful and delivered promising, new NNRTIs, whose formulation should be facilitated.
Notably, compound 4d has similar potency as etravirine in infected T-cell assays using WT
HIV-1 (IIIB) as well as viral variants that incorporate the two most commonly found
resistance mutations in the RT enzyme, Tyr181Cys and Lys103Asn.2 However, the
solubility of 4d is ca. 100-fold greater than for the diarylpyrimidines dapivirine (8a),
etravirine, and rilpivirine. Further fine-tuning of properties and activities can be envisioned
now that the benefits of exploration of the NNRTI entrance channel are clear.
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Figure 1.
Computed structure for the complex of 4b with WT HIV-1 reverse transcriptase. Carbon
atoms of 4b in yellow. Some residues removed for clarity.
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Scheme 1.
Synthesis of 3 (X = CH) and 4 (X = N). Reagents: (a) DIPEA THF, rt, overnight; (b)
DIPEA, THF, 65 °C, 2 days; (c) NaH, THF, rt, overnight; (d) H2/Pd-C.
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Scheme 2.
Synthesis of 10a and 10b. Reagents: (a) NaH, ACN, 70 °C, overnight; (b) TFA, DCM, 0 °C
to rt, 15 min.
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Table 2
Aqueous Solubility at pH 6.5 (S)
Compound S, μg/mL Compound S, μg/mL
8a 0.15 4d 14.2
3a 12.5 4e 22.9
3b 27.3 4i 25.4
9a 0.20 nevirapine 167a
4a 4.42 efavirenz 68.0
4b 15.3 etravirine ≪ 1b
4c 13.3 rilpivirine 0.02,c 0.24d
a
Ref. 14.
b
Ref. 11.
c
Ref. 4, pH 7.
d
Ref. 21, pH 7.4.
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